Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
HemSys_Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study
Oncotarget. 2016; 7: 85573-85583. Retrieved from https://www.oncotarget.com/article/10764/text/
En savoir plus
Calym
HemSys_Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life
Am J Hematol, 93: E329-E331. https://doi.org/10.1002/ajh.25217
En savoir plus
Calym
HemSys_Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement
Cancers 2021, 13(12), 2945; https://doi.org/10.3390/cancers13122945
En savoir plus
Calym
HemSys_Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
Neuro-Oncology, Volume 18, Issue 9, September 2016, Pages 1297–1303, https://doi.org/10.1093/neuonc/now033
En savoir plus
Calym
HemSys_Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study
Leukemia & Lymphoma, 56:7, 2025-2031, DOI: 10.3109/10428194.2014.977884
En savoir plus
Lysa
2022_LYSA_A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
doi: 10.1038/s41591-022-01969-y.
En savoir plus
Lysa
2022_LYSA_PET-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T-cells
doi: 10.3324/haematol.2021.280550.
En savoir plus
Lysa
2022_LYSA_Interpretation of 2-[ 18 F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors
Eur Radiol . 2022 Sep;32(9):6536-6544.
En savoir plus
Lysa
2022_LYSA_Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations
Mod Pathol . 2022 Aug;35(8):1126-1136.
En savoir plus
Lysa
2022_LYSA_Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)
Br J Haematol . 2022 Jul;198(1):203-206.
En savoir plus
Lysa
2022_LYSA_Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study
Haematologica . 2022 Jul 1;107(7):1681-1686.
En savoir plus
Lysa
2022_LYSA_Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with Mantle Cell lymphoma, a LYSA retrospective study
Bone Marrow Transplant . 2022 Apr;57(4):627-632.
En savoir plus
Lysa
2022_LYSA_The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma
Blood . 2022 Jan 20;139(3):384-398.
En savoir plus
Lysa
2022_LYSA_Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study
doi: 10.1080/10428194.2022.2107204.
En savoir plus
Lysa
2022_LYSA_Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
J Clin Oncol . 2022 Aug 10;JCO2200843.
En savoir plus
Lysa
2022_LYSA_Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
doi: 10.1200/JCO.21.01281.
En savoir plus
Lysa
2022_LYSA_High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline
doi: 10.3324/haematol.2021.280004
En savoir plus
Lysa
2022_LYSA_Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial
10.1182/bloodadvances.2022007609.
En savoir plus
Lysa
2022_Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes
Leukemia 2022;36:2835-2844
En savoir plus
Lysa
2022_Mature T-cell neoplasms and stem cell transplant: the never-ending story
Haematologica 2022;107:2534-2535
En savoir plus
Lysa
2022_Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study
J Nucl Med 2022;63:1149-1154
En savoir plus
Lysa
2022_LYSA_Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation
Am J Surg Pathol 2022;46:742-753
En savoir plus
Lysa
2022_LYSA_Oncogenetic landscape of lymphomagenesis in coeliac disease
Gut . 2022 Mar;71(3):497-508.
En savoir plus
Lysa
2022_LYSA_PET-driven strategy in advanced Hodgkin lymphoma: prolonged follow-up of the AHL2011 Phase III LYSA study
J Clin Oncol . 2022 Apr 1;40(10):1091-1101.
En savoir plus